Founder of Cambridge BioPartners, Inc.
Joined March 2009
- Tweets 45,129
- Following 6,337
- Followers 10,455
- Likes 173,895
2,058 Photos and videos
Pinned Tweet
8 Jun 2023
New Journal of Clinical Oncology @JCO_ASCO paper estimated potential savings of $661.8M for US taxpayer-funded Medicare if replace current Medicare Part D median formulary prices w/ @costplusdrugs pricing for 7 generic oncology drugs. ascopubs.org/doi/full/10.120… h/t @RuchikaTalwarMD
15
10
65
49,015
23h
Every non-US company sees how they can be cut off from US vendors with a snap of a finger. What does this mean for US AI labs’ offices and employees outside the US?
Jun 13
Well this is massive:
- Every non-US company sees how they can be cut off from US vendors with a snap of a finger. Non-US vendors getting free advertisement
- What does this mean for US AI labs’ offices and employees outside the US? Reads pretty draconian
What a mess
1
561
Pearl Freier retweeted
Jun 13
This is pretty freaking cool
Jun 12
A man working as a welder at SpaceX for $28 an hour has just become a millionaire.
Juan Hernandez, who came from Mexico, welded rockets for SpaceX at $28 an hour.
SpaceX gave him $10,000 in stock when he went full time in 2015, and he bought more with every paycheck for 10 years.
$SPCX is now trading at $167, making his shares worth over $1 million.
13
20
496
76,728
Pearl Freier retweeted
Jun 12
Hopkins will provide $280M in mid-size and large grants to support faculty for 2 years
(1) $160M for all life scientists (from basic to translation)
(2) $120M for all science and engineering.
This cannot replace federal funding, not even close, but it helps.
5
52
314
23,799
Pearl Freier retweeted
Jun 11
Jeff Bezos and Vik Bajaj give a first peek at Prometheus, an ARCH co-founded company to create an artificial general engineer. ARCH’s largest investment ever, from seed formation.
CNBC's David Faber sits down for an exclusive interview with Prometheus co-founders and co-CEOs Jeff Bezos and Vik Bajaj.
Tune in to CNBC to watch live and follow this thread for updates. ⬇️ cnbc.com/2026/06/11/project-…
13
72
18,663
Pearl Freier retweeted
Jun 9
every year @newlimit, we host friends at the lab & share our progress
for 2026, we announced:
- 2X increase in discovery rates with AI systems
- new program for endothelial cells
- 0 -> 1 medicines headed to the clinic
- accelerating recovery from alcohol
some highlights --
14
30
242
241,068
Pearl Freier retweeted
Jun 10
spoke w/Parabilis Medicines CEO about the biotech's record-breaking IPO
"People do ask sometimes about the SpaceX IPO and whether it would draw capital away from the biotech industry. I don’t think so. We’re going for our own moonshot right now."
$PBLS
endpoints.news/parabilis-ceo…
1
5
19
3,212
Pearl Freier retweeted
Jun 10
My family and I came to the US from Kyiv in '91 with a few hundred dollars and a willingness to work hard. I owe everything to this great nation and am very proud to be an American by choice. Grateful to share my story with @CNBC.
From refugee to entrepreneur, @mlevchin reflects on the experiences and principles that have shaped his career in @CNBC's America: 250 Years Bold series.
bit.ly/4xnX6Ju
4
6
82
12,550
Pearl Freier retweeted
Largest rare tumor immunotherapy study ever. Opened at over 1000 sites. Overall response rates low— but a subgroup of refractory patients across multiple cohorts have exceptional responses (ongoing for years) without biomarkers.
DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers - Final results (full access link below) thanks to all esp the patients involved in the 1st NCI rare tumor IO basket study! sciencedirect.com/science/ar…
7
48
12,002
Pearl Freier retweeted
Jun 11
Over the past two years, Genentech has laid off or lost Ira Mellman, Shannon Turley, and now Vishva Dixit!
What is happening at Genentech?
Jun 11
SCOOP: Roche’s Genentech underwent another round of layoffs this week in its early research and development group, Endpoints News has learned, which included shuttering two research units and the departure of several senior researchers.
My latest here: endpoints.news/exclusive-gen…
11
13
105
51,843
Jun 10
Interesting comments on interviewing & reference checks. Would candidates agree to reference checks before being interviewed though? Could do unofficial reference checks to see if you want to interview someone which is what many hiring mgrs do already
Jun 9
Former CRO of @Meta David Fischer: most people do reference checks backwards.
You do five rounds of interviews, the team's excited about this person, you've basically decided on the hire already. Only then do you call the references to make sure there's no huge red flag.
At that point, David says, you're not learning, you're confirming.
He approaches hiring with reference-checking first, with a key calibration question: "If you were starting a company tomorrow and making your first sales hire, would this person be it?"
1
574
Jun 10
"It's truly the hottest thing in medicine." Chart below from @brianreid shows monthly site visits for a new US government website that claims to be "delivering the lowest prescription prices in the world for Americans." The number of site visits have declined since February.
1
2
738
Jun 10
I can't recall the last time I saw a new company focused on Thyroid Eye Disease (TED) & Graves' disease (GD) emerge w/ this level of backing. Significant unmet medical need remains in these chronic autoimmune diseases which are influenced by both genetic & environmental factors. TED can have a profound impact on quality of life & disproportionately affects women. More below on a potentially best-in-class anti-TSHR antibody for TED & GD. Ethyreal Bio plans to initiate first-in-human clinical trials in the second half of 2026.
Jun 10
Excited to have Ethyreal Bio emerge from stealth today!
Ethyreal Bio raises $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease
globenewswire.com/news-relea…
2
5
3,443
Pearl Freier retweeted
A thoughtful and easy read from Angie You (@Angiejyou) on basic research as a driver of next-generation therapeutics, noting here clinical data from Revolution Medicines linkedin.com/posts/angie-you…
4
15
2,390
Jun 8
The recent breakthrough in pancreatic cancer therapy isn't a cure. But it *may be* a pathway to one.
Pancreatic cancer has miserable survival rates. Most cases are driven by RAS, a protein long considered basically undruggable.
Revolution Medicines found a way to target RAS with daraxonrasib, which nearly doubled median overall survival versus chemo, and was easier to tolerate.
Crucially, being able to target RAS gives pancreatic cancer therapy a new foundation. Other drugs can be layered on top of daraxonrasib to even better results than the drug alone.
@drsamuelbhume explains:
2
1,531
Jun 8
The 1st patient was dosed on June '25 in the study of Tango Therapeutics' PRMT5 inhibitor drug vopimetostat in combo w/ Revolution Medicine's RAS(ON) inhibitor daraxonrasib. Data below. I wonder if AI was used for clinical trial enrollment/recruitment? $TNGX $RVMD $XBI
More good news in pancreatic cancer:
Daraxonrasib recently doubled survival in metastatic disease in Phase 3. Now, combined with vopimetostat, it has shown a 92% objective response rate. This is far above the 25–35% seen with either drug alone.
Thread below 👇
9
2,098
Jun 8
Did you know that Nobel laureate Carolyn Bertozzi, in the news today for Firefly Bio, was in a college rock band with future Rage Against the Machine co-founder Tom Morello?
Jun 8
Without a doubt you would never know it (in a good way) when you meet and speak with her.
2
5
2,007
Jun 8
RT @Sanctuary_Bio: @PearlF It's pretty impressive. Synthetic lethality has been a tough nut to crack. Maybe we are finally getting there...
1